Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 63 Show results per page	View Search Criteria \| Help With Results


1.		Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				Not specified				NHLBI				557 U01 HL072305-01, HL072268, HL072291, HL072196, HL072248, HL072191, HL072305, HL072028, HL072072, HL072355, HL072283, HL072346, HL072331, HL072290, NCT00627393

Last Modified: 7/10/2007 First Published: 5/1/2001


2.		Phase I/II Pilot Study of Non-Myeloablative Chemotherapy Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Hematopoietic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				4 to 21				NCI				NCI-01-C-0125F NCT00020592

Last Modified: 10/23/2008 First Published: 5/1/2002


3.		Phase II Study of a Non-Myeloablative Conditioning Regimen Comprising Fludarabine and Total Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Imatinib Mesylate, Dasatinib, or Nilotinib-Responsive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Blast Crisis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				NCI				FHCRC-1581.00 5235, NCI-H02-0087, NCT00036738

Last Modified: 6/7/2006 First Published: 10/1/2002


4.		Phase I/II Study of Alemtuzumab-Based Conditioning Followed By HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Advanced Mycosis Fungoides/Sezary Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				NHLBI				NHLBI-02-H-0250 NCT00047060

Last Modified: 12/9/2008 First Published: 11/24/2002


5.		Phase I/II Pilot Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced Myelodysplastic Syndromes (MDS), Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), or Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				75 and under				NCI				FHCRC-1655.00 5430, NCT00052520

Last Modified: 10/21/2008 First Published: 8/24/2003


6.		Phase I/II Study of Donor Lymphocyte Infusion in Patients With Persistent, Relapsed, or Progressing Malignancy After Nonmyeloablative Allogeneic Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Any age				NCI				FHCRC-1803.00 5606, NCT00068718


7.		Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				H8713 NCT00058825

Last Modified: 10/29/2008 First Published: 10/25/2004


8.		Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Under 75				NCI, Pharmaceutical / Industry				FHCRC-1825.00 5605, SUPERGEN-FHCRC-1825.00, NCT00096161

Last Modified: 1/14/2009 First Published: 10/21/2005


9.		Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 75				NCI				OHSU-HEM-05011-L OHSU-210, NCT00245037


10.		Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for AML and MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				2005-0508 NCT00402558

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute